NeoRx Corp. and Sterling Winthrop Inc. said Monday they havesigned a definitive agreement announced in June.

Sterling Winthrop gains a nonexclusive license to use some ofNeoRx's proprietary technology for labeling antibodies andother kinds of targeting proteins with therapeutic radiometalsfor cancer therapy. NeoRx also gave Sterling Winthropexclusive rights to certain antibodies for use inradioimmunotherapy of cancer and nonexclusive rights to theseantibodies for other forms of cancer therapy.

In return, NeoRx received $1.5 million in cash and 2 millionshares of NeoRx common stock held by Sterling Winthrop.NeoRx will also receive $500,000 upon the transfer ofinformation to Sterling Winthrop, which will pay a royalty onthe sales of products that incorporate licensed NeoRxtechnology and antibodies.

(c) 1997 American Health Consultants. All rights reserved.